ebselen has been researched along with Antibiotic-Associated Colitis in 1 studies
ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garland, M | 1 |
| Hryckowian, AJ | 1 |
| Tholen, M | 1 |
| Bender, KO | 1 |
| Van Treuren, WW | 1 |
| Loscher, S | 1 |
| Sonnenburg, JL | 1 |
| Bogyo, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Parallel Group, Double Blind, Placebo Controlled, Add on Clinical Trial to Investigate Whether the Lithium Mimetic, Ebselen, Can Reduce Symptoms of Hypomania and Mania in Bipolar Patients[NCT03013400] | Phase 2 | 60 participants (Actual) | Interventional | 2017-10-01 | Completed | ||
| Phase 1b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of SPI-1005 in Meniere's Disease[NCT02603081] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus[NCT00762671] | Phase 2/Phase 3 | 60 participants (Actual) | Interventional | 1999-05-31 | Completed | ||
| A Phase 1, Double-blind, Placebo-controled, Randomized Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SPI-1005 (Ebselen)in Healthy Adult Subjects[NCT01452607] | Phase 1 | 32 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for ebselen and Antibiotic-Associated Colitis
| Article | Year |
|---|---|
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |